Axcelead Presents Multi-Cell-Line Proteomics Platform for TPD Off-Target Safety Assessment at JSOT 2026

As targeted protein degraders advance toward IND submission, the adequacy of off-target toxicity data is drawing sharper regulatory scrutiny, and Axcelead Drug Discovery & Development is presenting a proteomics-based safety assessment framework designed to address that gap. Dr. Qinge Liang, from Axcelead's Translational Research Business Unit, will deliver both an oral and a poster presentation at the 53rd Annual Meeting of the Japanese Society of Toxicology (JSOT), held at the Osaka International Convention Center on July 1, 2026.

The presentation, titled Proteomic Analysis for Off-Target Risk Assessment of Targeted Protein Degraders, centers on a multi-cell-line global proteomics platform validated against two representative TPDs. The core problem it addresses is methodological: single-cell-line proteomics analyses routinely miss neo-substrate degradation events because neo-substrate expression is cell- and tissue-specific. A three-cell-type human-derived panel detected approximately 10,000 proteins in total, achieving coverage of known neo-substrates, including those with documented safety signals, that single-line approaches cannot reliably provide.

For preclinical safety leads and IND package authors, the dose-response component carries particular weight. By extracting proteins that decrease in a concentration-dependent manner, the platform improves discrimination between incidental and true off-target degradation events. Identified degraded proteins are then mapped to toxicity-related phenotypic annotations, lethality, oncogenicity, developmental abnormalities, generating a risk profile structured for regulatory interpretation rather than internal research use alone.

The practical implication for CRO-sponsor collaborations is that a multi-cell-line proteomics readout, structured around phenotypic annotation, could form a defensible component of the nonclinical safety section of an IND package, particularly as agencies increase expectations around mechanistic characterization of TPD-induced degradation beyond the intended target. The platform's ability to surface unknown off-target proteins at scale positions it as an early-stage screening tool rather than a late-cycle confirmatory assay.

The oral session runs from 9:30 to 10:48 on July 1; the poster session follows from 13:30 to 14:30, Poster Board No. 5183.

The measurable benchmark to watch is whether the multi-cell-line panel's neo-substrate coverage rate holds across a broader set of TPD chemotypes beyond the two representative compounds used in this validation study.

Source: Axcelead Drug Discovery & Development via axcelead-us.com, June 19, 2026.